
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
about 24 years ago
Toward Effective Enhancement of Clinical Qualityabout 24 years ago
Understanding Health and Healthcare Total Costs: A Novel Perspective





